Unknown

Dataset Information

0

Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence.


ABSTRACT: Purpose of review:HIV-infected (HIV+) and hepatitis C virus-infected (HCV+) individuals with end-stage renal disease (ESRD) have decreased access to kidney transplantation. With new opportunities provided by the HIV Organ Policy Equity (HOPE) Act and direct-acting antivirals (DAAs) for HCV, we explore the potential risks and benefits of living donor kidney transplantation from HIV+ or HCV+ donors, from the perspective of both donor health and recipient outcomes. Recent findings:The HOPE Act permits organ donation from both deceased and living HIV+ persons to HIV+ recipients; however, there is only clinical experience with HIV+ deceased donors to date. Empirical evidence demonstrates a low but acceptable risk of ESRD in potential HIV+ living donors without comorbidities who have well-controlled infection in the absence of donation. With the availability of potent DAAs for eradication of HCV infection, growing evidence shows good outcomes with HCV seropositive and/or viremic deceased kidney donors, providing rationale to consider HCV+ living donors. Summary:HIV+ and HCV+ living donor kidney transplantation may improve access to transplant for vulnerable ESRD populations. Careful evaluation and monitoring are warranted to mitigate potential risks to donors and recipients.

SUBMITTER: Liyanage L 

PROVIDER: S-EPMC7449146 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Living kidney donation in individuals with hepatitis C and HIV infection: rationale and emerging evidence.

Liyanage Luckmini L   Muzaale Abimereki D AD   Henderson Macey L ML   Durand Christine M CM  

Current transplantation reports 20190430 2


<h4>Purpose of review</h4>HIV-infected (HIV+) and hepatitis C virus-infected (HCV+) individuals with end-stage renal disease (ESRD) have decreased access to kidney transplantation. With new opportunities provided by the HIV Organ Policy Equity (HOPE) Act and direct-acting antivirals (DAAs) for HCV, we explore the potential risks and benefits of living donor kidney transplantation from HIV+ or HCV+ donors, from the perspective of both donor health and recipient outcomes.<h4>Recent findings</h4>Th  ...[more]

Similar Datasets

| S-EPMC8292201 | biostudies-literature
| S-EPMC9089923 | biostudies-literature
| S-EPMC9869859 | biostudies-literature
| S-EPMC4663050 | biostudies-literature
| S-EPMC6815694 | biostudies-literature
| S-EPMC7923981 | biostudies-literature
| S-EPMC5586566 | biostudies-literature
| S-EPMC10809017 | biostudies-literature
| S-EPMC7019428 | biostudies-literature
| S-EPMC10364766 | biostudies-literature